Harnessing the innate immune response to treat small cell lung cancer
Description: Small cell lung cancer (SCLC) is an incredibly aggressive form of lung cancer with limited treatment options, begging the need for major therapeutic breakthroughs in order to increase poor (less than 7%) survival rates of patients. This proposal will take advantage of our state-of-the-art experimental model systems to provide robust preclinical evidence for the use of NK cell immunotherapy in the treatment of SCLC primary and metastatic disease.
Amount: A$1,057,000
Funding type: research
Funder scheme: Project Grants - Standard Project Grant
Investigator: Kate Sutherland
Institution: Walter and Eliza Hall Institute of Medical Research
Funded outputs count: 6
Funder award ID: 1159955
OpenAlex ID: G7437865231